New Delhi: OneSource Specialty Pharma Ltd on Tuesday announced a manufacturing partnership for biosimilars with Munich-based Formycon AG, an independent biosimilar developer.Under the partnership, OneSource will serve as a strategic manufacturing partner for Formycon and provide integrated Drug Substance (DS) and Drug Product (DP) manufacturing capabilities from its biologics' facility in Bengaluru, the company said in a statement."This partnership brings together Formycon's development expertise and OneSource's integrated manufacturing capabilities to expand access to high-quality, affordable biologics for patients worldwide," OneSource Specialty Pharma Managing Director & CEO Neeraj Sharma said.Also read: FDA approves at-home starter dose of Eisai-Biogen Alzheimer's drugHe further said, "It also reinforces our belief that India is uniquely positioned to serve as a global hub for the development and manufacture of world-class biologics."Formycon AG CEO Stefan Glombitza said, "By adding OneSource to our network of strategic manufacturing partners, we are further strengthening our supply capabilities with a partner that meets our unwavering commitment to high standards of quality, operational excellence and cost-efficiency.""We aim to broaden sustainable global access to life-changing biosimilar therapies, " said Glombitza.
OneSource Specialty Pharma partners with Formycon AG to manufacture biosimilars
OneSource Specialty Pharma has announced a manufacturing partnership for biosimilars with Formycon AG. This collaboration will see OneSource providing integrated manufacturing capabilities for biosimilars. The partnership aims to expand access to high-quality, affordable biologics for patients globally. Formycon AG CEO stated this strengthens their supply capabilities with a quality-focused partner. Both companies aim to broaden sustainable global access to life-changing biosimilar therapies.








